1. 252-OR: Virtual Multidisciplinary Lifestyle Intervention Is as Effective as the Physical Program for Patients with Diabetes and Obesity during COVID-19 Pandemic
- Author
-
Jennie L. Votta, Jacqueline Shahar, Chandra L. Davis, Joan M. Beaton, Marwa R. Al-Badri, Cara L. Kilroy, Aaron M. Price, Jo-Anne M. Rizzotto, Hannah Gardner, Osama Hamdy, Shaheen Tomah, Aliza Phillips-Stoll, and Mallory Sin
- Subjects
medicine.medical_specialty ,education.field_of_study ,medicine.diagnostic_test ,business.industry ,Endocrinology, Diabetes and Metabolism ,Population ,Type 2 diabetes ,medicine.disease ,Obesity ,Diabetes management ,Weight loss ,Internal medicine ,Diabetes mellitus ,Weight management ,Internal Medicine ,medicine ,medicine.symptom ,education ,Lipid profile ,business - Abstract
Intensive lifestyle intervention (ILI) is essential for diabetes management. The Weight Achievement and Intensive Treatment (Why WAIT) program is a 12-week multidisciplinary weight management program that has been implemented in real-world clinical practice and has shown long-term maintenance of weight reduction for 5 years. During COVID-19 pandemic, the program went virtual using telemedicine and mobile-applications (Healthimation and Good Measures™). We evaluated the outcomes of virtual program (VP) in comparison to in-person physical program (PP). Sixteen subjects were enrolled in VP and were compared to 22 subjects who completed the last 2 PPs. Body weight decreased by -16.49±8 lbs. (-7 % ± 0.3%) from baseline in VP (p In conclusion, virtual multidisciplinary ILI is as effective as the in-person physical program in improving body weight, A1C, BP, lipid profile and in reducing the number of anti-hyperglycemic medications. These results suggest that scaling the Why WAIT program in a virtual format to a larger population of patients with diabetes and obesity is potentially as successful as the costly in-person program. Disclosure M. Al-badri: None. J. M. Beaton: None. C. L. Davis: None. J. M. Rizzotto: None. O. Hamdy: Advisory Panel; Self; Nestlé, Consultant; Self; Abbott, AstraZeneca, Sanofi, Research Support; Self; Eli Lilly and Company, Gilead Sciences, Inc., National Dairy Council, Novo Nordisk, Stock/Shareholder; Self; Healthimation, LLC. C. L. Kilroy: None. J. I. Shahar: None. S. Tomah: Stock/Shareholder; Self; Amarin Corporation plc. H. Gardner: None. M. Sin: None. J. L. Votta: None. A. Phillips-stoll: None. A. M. Price: None.
- Published
- 2021